SeraCare Launches Anti-Dengue Performance Panel

SeraCare Life Sciences has announced the launch of the first commercially available Anti-Dengue Mixed Titer Performance Panel. This new addition to the SeraCare line of infectious disease panels responds to growing demand for accurate testing for dengue virus, which infects an estimated 50 to 100 million people annually, according to the World Health Organization.

“Forty percent of the world’s population lives in areas at risk for dengue transmission,” said Chris Long, Associate Product Manager at SeraCare Life Sciences. “Continued increases in global travel and immigration raise the risk of dengue virus transmission worldwide, well beyond the countries in which it is endemic. The new SeraCare Anti-Dengue Performance Panel responds to the rising world health issue and the corresponding need for assays that are well-challenged for accuracy and sensitivity.”

The SeraCare Anti-Dengue Mixed Titer Performance Panel is designed to help blood donor collection facilities, diagnostics manufacturers and clinical laboratories evaluate and troubleshoot their anti-dengue virus assays. “The panel will enable our customers to have greater confidence in their dengue test results, knowing that their assays have been rigorously challenged,” adds Chris Long.

The new performance panel is derived from undiluted, unpreserved human plasma specimens, with 21 members representing a wide range of reactivity for anti-dengue IgM and IgG antibodies, from negative to strongly positive. Panel members include samples from individuals with recent and past infection by all four dengue viruses (DENV-1 through DENV-4).

The SeraCare Anti-Dengue Mixed Titer Performance Panel is available for purchase immediately worldwide. For ordering information, click on the ‘request information’ tab below or follow the company website link.